Somatostatin Receptor Imaging with [18F]FET-{beta}AG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study
Suraiya Dubash,Tara D Barwick,Kasia Kozlowski,Andrea G Rockall,Sairah Khan,Sameer Khan,Siraj Yusuf,Angela Lamarca,Juan W Valle,Richard A Hubner,Mairéad G McNamara,Andrea Frilling,Tricia Tan,Florian Wernig,Jeannie Todd,Karim Meeran,Bhavesh Pratap,Saleem Azeem,Michael Huiban,Nicholas Keat,Jingky P Lozano-Kuehne,Eric O Aboagye,Rohini Sharma,Tara D. Barwick,Andrea G. Rockall,Juan W. Valle,Richard A. Hubner,Mairéad G. McNamara,Jingky P. Lozano-Kuehne,Eric O. Aboagye
DOI: https://doi.org/10.2967/jnumed.123.266601
2024-03-02
Journal of Nuclear Medicine
Abstract:There is a clinical need for 18 F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [ 68 Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [ 18 F]fluoroethyl-triazole-[Tyr 3 ]-octreotate ([ 18 F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [ 18 F]FET-βAG-TOCA PET/CT compared with [ 68 Ga]Ga-DOTA- peptide PET/CT in patients with NET. Methods: Forty-five patients with histologically confirmed NET, grades 1 and 2, underwent PET/CT imaging with both [ 18 F]FET-βAG-TOCA and [ 68 Ga]Ga-peptide performed within a 6-mo window (median, 77 d; range, 6–180 d). Whole-body PET/CT was conducted 50 min after injection of 165 MBq of [ 18 F]FET-βAG-TOCA. Tracer uptake was evaluated by comparing SUV max and tumor-to-background ratios at both lesion and regional levels by 2 unblinded, experienced readers. A randomized, blinded reading of both scans was also then undertaken by 3 experienced readers, and consensus was assessed at a regional level. The ability of both tracers to visualize liver metastases was also assessed. Results: A total of 285 lesions were detected on both imaging modalities. An additional 13 tumor deposits were seen in 8 patients on [ 18 F]FET-βAG-TOCA PET/CT, and [ 68 Ga]Ga-DOTA-peptide PET/CT detected an additional 7 lesions in 5 patients. Excellent correlation in SUV max was observed between both tracers ( r = 0.91; P < 0.001). No difference was observed between median SUV max across regions, except in the liver, where the median tumor-to-background ratio of [ 18 F]FET-βAG-TOCA was significantly lower than that of [ 68 Ga]Ga-DOTA-peptide (2.5 ± 1.9 vs. 3.5 ± 2.3; P < 0.001). Conclusion: [ 18 F]FET-βAG-TOCA was not inferior to [ 68 Ga]Ga-DOTA-peptide in visualizing NET and may be considered in routine clinical practice given the longer half-life and availability of the cyclotron-produced fluorine radioisotope.
radiology, nuclear medicine & medical imaging